BioSpace News Archive

Tiziana Life Sciences announced that Dr. Tanuja Chitnis, MD, Professor of Neurology and the Principal investigator of the clinical study at the at the Brigham and Women’s Hospital, Boston, MA., will be presenting a poster discussing clinical data from a patient with secondary progressive Multiple Sclerosis, who was treated with intranasal foralumab for six months.

Karyopharm Therapeutics Inc. announced that the Company’s senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m. ET in New York, NY.

CytoSorbents Corporation today announced that following a successful pilot program in three countries, the Company has signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (Nikkiso) to distribute their PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries.

SciNeuro Pharmaceuticals (SciNeuro), a leader in the discovery and development of innovative therapeutics for the treatment of CNS diseases, today announced the execution of an exclusive, worldwide license and option agreement with GlaxoSmithKline (GSK).

Wide range of research across tumor types underscores Servier’s commitment to discovering novel approaches to addressing difficult-to-treat cancers.

Bristol Myers Squibb announced positive results from the Phase 2 PAISLEY study evaluating deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, compared to placebo in patients with moderate to severe systemic lupus erythematosus.

Bicycle Therapeutics plc announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 8:00 a.m. ET.

Greenbrook TMS Inc. (TSX: GTMS) (“ Greenbrook ” or the “ Company ”) is pleased to announce that it will host a webcast investor presentation on Tuesday, June 7th, 2022, at 2:00 PM ET.

BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY from June 8-10, 2022.

The Lupus Research Alliance and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus.